upus erythematosus panniculitis (LEP) is a subset of chronic cutaneous lupus erythematosus that presents with indurated nodules primarily located in the head and neck that heal with pronounced lipoatrophy. 1 Lupus erythematosus panniculitis is a rare, progressive, and disfiguring disease, which affects patient quality of life. No wellestablished, effective treatment protocols exist for LEP. Traditionally, antimalarials have been considered first-line therapy. [1][2][3][4] Systemic corticosteroids, methotrexate, and mycophenolate mofetil have all been used in the treatment of LEP, with variable outcomes. 2,3,5 There are emerging reports on the successful use of rituximab in LEP. [6][7][8][9] Rituximab is well established in the management of systemic lupus erythematosus (SLE) 10 and has been used successfully in the treatment of cutaneous-predominant SLE and refractory subacute chronic cutaneous lupus erythematosus. 11,12 We report 4 cases of childhood-onset LEP resistant to other therapies that were successfully treated with rituximab.
MethodsWe conducted a retrospective case series of 4 patients with childhood-onset LEP presenting to our pediatric dermatology and rheumatology clinics between July 1, 2014, and July 1, 2018. The University of Minnesota Institutional Review Board determined that this project was not human participants research and waived the need for institutional review board approval. All patients and/or parents provided written consent to be part of this case series.
Case SeriesPatient 1 was an otherwise healthy adolescent who presented with recurrent, tender, disfiguring facial nodules (Figure 1A). He was examined by an otolaryngologist, who IMPORTANCE Childhood-onset lupus erythematosus panniculitis (LEP) is a rare and chronic disfiguring disease. A paucity of literature exists on the clinical manifestations of this disease and how best to treat it.OBJECTIVES To describe the clinical features of childhood-onset LEP and report on the use of rituximab in treatment-refractory childhood-onset LEP.
DESIGN, SETTING, AND PARTICIPANTSA retrospective, observational case series study was conducted of 4 patients with childhood-onset LEP who presented to a single-center, tertiary care clinic with pediatric dermatology and pediatric rheumatology clinics between July 1, 2014, and July 1, 2018, and were treated with rituximab. A literature review was conducted of the clinical features and treatment of childhood-onset LEP.EXPOSURE Rituximab therapy for childhood-onset LEP.
MAIN OUTCOMES AND MEASURESReduction in the number and size of erythematous and tender subcutaneous nodules (both visually and by palpation), reduction of facial atrophy (documented with serial photography), and tolerability of rituximab at 2 to 22 months after initiation of therapy.RESULTS Four patients (3 male; mean [SD] age at treatment, 15 [5.9] years) with refractory childhood-onset LEP were successfully treated with rituximab. All patients had a rapid and sustained response to therapy with rituximab. One patient (25%) had minor infusi...